India, July 5 -- Seer, Inc. (SEER), a proteomics company, on Thursday announced receipt of an unsolicited, non-binding acquisition proposal from the Chief Executive Officer (CEO) and Chair of the company, Omid Farokhzad.
Farokhzad offered to purchase all of the company's outstanding Class A shares at $2.45 per share in cash, plus two separate contingent value rights.
CEO Farokhzad also founded the company in 2017 and has served as Chairman of the board since. He previously founded BIND Therapeutics and Selecta Biosciences prior to their respective acquisition and merger.
For comments and feedback contact: editorial@rttnews.com
Published by HT Digital Content Services with permission from RTT News....